Long-term basal therapy using insulin degludec in Type 1 diabetes required lower doses and was associated with a 25% lower risk for nocturnal hypoglycaemia than insulin glargine (Diabetic Medicine)
Diabetes News Service
Long-term basal therapy using insulin degludec in Type 1 diabetes required lower doses and was associated with a 25% lower risk for nocturnal hypoglycaemia than insulin glargine (Diabetic Medicine)
A Glycosmedia iPhone/iPad App is available FREE from the iTunes store.
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
This site complies with the HONcode standard for trustworthy health information: verify here.
Website by Wired up Wales